Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Feb;11(2):214–218. doi: 10.1128/aac.11.2.214

Pharmacokinetics of Amikacin During Hemodialysis and Peritoneal Dialysis

Lisbeth Regeur 1, Hanne Colding 1, Herluf Jensen 1, Jens P Kampmann 1
PMCID: PMC351955  PMID: 848923

Abstract

The pharmacokinetics of amikacin were examined in six bilaterally nephrectomized patients undergoing hemodialysis and in four patients with a minimal residual renal function undergoing peritoneal dialysis. The mean elimination half-life before the dialysis was 86.5 h in the anephric patients and 44.3 h in the patients with minimal residual kidney function. The results from the anephric patients suggest that some extrarenal elimination of amikacin may occur. The mean volume of distribution was about 25% of the total body weight. This is in accordance with values reported from subjects with normal renal function. During hemodialysis the half-life decreased to less than 10% (5.6 h) of the pretreatment value. The effectiveness of peritoneal dialysis was less as the half-life decreased to only about 30% (17.9 h) of the pretreatment value. During the dialyses a significant correlation between the half-life of amikacin and the decrease in blood urea and serum creatinine was demonstrated. The pharmacokinetic data were used to make dosage regimen recommendations for the treatment of patients undergoing intermittent hemodialysis or peritoneal dialysis.

Full text

PDF
214

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altmann G., Bogokowsky B., Boner G., Eliahou H. E. Blood levels of ampicillin, kanamycin and gentamicin in the uremic patient. Isr J Med Sci. 1970 Nov-Dec;6(6):683–690. [PubMed] [Google Scholar]
  2. Amikacin. Lancet. 1975 Oct 25;2(7939):804–805. [PubMed] [Google Scholar]
  3. Atkins R. C., Mion C., Despaux E., Nguyen-Van-Hai, Julien C., Mion H. Peritoneal transfer of kanamycin and its use in peritoneal dialysis. Kidney Int. 1973 Jun;3(6):391–396. doi: 10.1038/ki.1973.61. [DOI] [PubMed] [Google Scholar]
  4. Black R. E., Lau W. K., Weinstein R. J., Young L. S., Hewitt W. L. Ototoxicity of amikacin. Antimicrob Agents Chemother. 1976 Jun;9(6):956–961. doi: 10.1128/aac.9.6.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bodey G. P., Valdivieso M., Feld R., Rodriguez V. Pharmacology of amikacin in humans. Antimicrob Agents Chemother. 1974 May;5(5):508–512. doi: 10.1128/aac.5.5.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cabana B. E., Taggart J. G. Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrob Agents Chemother. 1973 Apr;3(4):478–483. doi: 10.1128/aac.3.4.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Christopher T. G., Korn D., Blair A. D., Forrey A. W., O'Neill M. A., Cutler R. E. Gentamicin pharmacokinetics during hemodialysis. Kidney Int. 1974 Jul;6(1):38–44. doi: 10.1038/ki.1974.75. [DOI] [PubMed] [Google Scholar]
  8. Clarke J. T., Libke R. D., Regamey C., Kirby W. M. Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther. 1974 Jun;15(6):610–616. doi: 10.1002/cpt1974156610. [DOI] [PubMed] [Google Scholar]
  9. Curtis J. R., McDonald S. J., Weston J. H. Parenteral administration of gentamicin in renal failure: patients undergoing intermittent haemodialysis. Br Med J. 1967 May 27;2(5551):537–539. doi: 10.1136/bmj.2.5551.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Danish M., Schultz R., Jusko W. J. Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrob Agents Chemother. 1974 Dec;6(6):841–847. doi: 10.1128/aac.6.6.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelly M. T., Matsen J. M. In vitro activity, synergism, and testing parameters of amikacin, with comparisons to other aminoglycoside antibiotics. Antimicrob Agents Chemother. 1976 Mar;9(3):440–447. doi: 10.1128/aac.9.3.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klastersky J., Nyamubeya B., Vandenborre L. Antimicrobial effectiveness ofkanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods. J Med Microbiol. 1974 Nov;7(4):465–472. doi: 10.1099/00222615-7-4-465. [DOI] [PubMed] [Google Scholar]
  13. Levy J., Klastensky J. Correlation of serum creatinine concentration and amikacin half-life. J Clin Pharmacol. 1975 Oct;15(10):705–707. doi: 10.1002/j.1552-4604.1975.tb05924.x. [DOI] [PubMed] [Google Scholar]
  14. Lockwood W. R., Bower J. D. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973 Jan;3(1):125–129. doi: 10.1128/aac.3.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Malacoff R. F., Finkelstein F. O., Andriole V. T. Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. Antimicrob Agents Chemother. 1975 Nov;8(5):574–580. doi: 10.1128/aac.8.5.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Reynolds A. V., Hamilton-Miller J. M., Brumfitt W. Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin. Br Med J. 1974 Sep 28;3(5934):778–780. doi: 10.1136/bmj.3.5934.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Riff L. J., Jackson G. G. Pharmacology of gentamicin in man. J Infect Dis. 1971 Dec;124 (Suppl):S98–105. doi: 10.1093/infdis/124.supplement_1.s98. [DOI] [PubMed] [Google Scholar]
  18. Rosdahl V. T., Vejlsgaard V., Rosdahl N., Vejlsgaard R. A micromethod for determination of antibiotics in serum. Dan Med Bull. 1969 May;16(5):133–139. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES